Melbourne, Sept 17, 2008 (ABN Newswire) - Australia’s regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), today announced that the United States Food and Drug Administration (FDA) has granted an orphan drug designation for the use of the patented adult stem cell technology in patients undergoing bone marrow transplantation.
